Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07062172 · ClinicalTrials.gov registry record · NA

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

A NA study of Lung Cancer and Driver Mutation, sponsored by University of California, Irvine.

Recruiting
Registry status
NA
Development phase
1,753
Enrollment target
1
Study location

NCT07062172 is a NA study of Lung Cancer and Driver Mutation that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 1,753 participants, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (88% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07062172, a NA study of Lung Cancer and Driver Mutation, is actively recruiting participants, sponsored by University of California, Irvine.

RECRUITING
Registry status
NA
Development phase
1,753 participants
Enrollment target
1
Study location

Study Summary

This is a single-armed screening research study which screens immediate family member of lung cancer patients with a driver mutation to see if lung cancer can be inherited and whether researchers can find lung cancer early. Immediate family members of lung cancer patients will be 40-80 years old and screened using a low dose CT scan.

Interventions

  • DIAGNOSTIC_TEST Low Dose CT Scan

Study Locations (1)

California

  • Chao Family Comprehensive Cancer Center University of California, Irvine - Orange

Trial Details

FieldValue
Enrollment Target 1,753 participants
Start Date 2025-05-08
Est. Completion 2028-12-31
Phase NA

Sponsor

University of California, Irvine

368 total trials

What the Registry Record Tells You About NCT07062172

The ClinicalTrials.gov registry entry for NCT07062172 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,753 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (88% higher). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Low Dose CT Scan is the first listed.

NCT07062172 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07062172 about?

NCT07062172 is a clinical study titled "Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer". This is a single-armed screening research study which screens immediate family member of lung cancer patients with a driver mutation to see if lung cancer can be inherited and whether researchers can find lung cancer early. Immediate family members of lung cancer patients will be 40-80 years old and...

What is the current status of trial NCT07062172?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,753 participants. The study started on 2025-05-08. Estimated completion is 2028-12-31.

What conditions does trial NCT07062172 study?

This clinical trial studies the following conditions: Lung Cancer, Driver Mutation.

What interventions are being tested in trial NCT07062172?

The interventions under investigation include: Low Dose CT Scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07062172?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07062172 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.